RPG Life Sciences Limited (NSE:RPGLIFE)
India · Delayed Price · Currency is INR | Market Cap | 39.93B +9.6% |
| Revenue (ttm) | 7.08B +8.3% |
| Net Income | 1.15B -37.1% |
| EPS | 69.64 -37.1% |
| Shares Out | 16.54M |
| PE Ratio | 34.67 |
| Forward PE | n/a |
| Dividend | 24.00 (0.97%) |
| Ex-Dividend Date | Jun 27, 2025 |
| Volume | 11,682 |
| Average Volume | 114,995 |
| Open | 2,480.00 |
| Previous Close | 2,463.10 |
| Day's Range | 2,409.00 - 2,480.00 |
| 52-Week Range | 1,733.00 - 2,725.00 |
| Beta | -0.20 |
| RSI | 72.02 |
| Earnings Date | Apr 29, 2026 |
About RPG Life Sciences
RPG Life Sciences Limited, an integrated pharmaceutical company, develops, manufactures, and markets branded formulations, generic, and synthetic active pharmaceutical ingredients (APIs) in India and internationally. The company offers synthetic APIs in various therapeutic categories, including immunosuppressants, anti-psychotic, anti-anginal, anthelmintics, anti-convulsant, anti-spasmodic, etc. It also provides generics for immunosuppressant therapy; and finished dosage formulations for various therapies, which include nephrology, rheumatology... [Read more]
Financial Performance
In fiscal year 2026, RPG Life Sciences's revenue was 7.08 billion, an increase of 8.28% compared to the previous year's 6.53 billion. Earnings were 1.15 billion, a decrease of -37.15%.
Financial StatementsNews
Q4 2026 RPG Life Sciences Ltd Earnings Call Transcript
Q4 2026 RPG Life Sciences Ltd Earnings Call Transcript
RPG Life Sciences Transcript: Q4 25/26
Q4 FY26 saw 23.6% revenue growth and 48% EBITDA growth, with strong domestic and API recovery. Margin stabilization is expected as the API plant is fully operational, and new product launches and market expansion are set to drive future growth.
RPG Life Sciences surges 11% to Rs 2,254 despite 74% profit fall — EBITDA growth and Rs 24 dividend tell the real story
RPG Life Sciences is up 11% on Wednesday, touching an intraday high of Rs 2,312.40, in what at first glance appears to be one of the more counterintuitive market reactions…
Why are RPG Life Sciences shares falling over 10% today? Explained
Shares of RPG Life Sciences fell sharply by over 10% in early morning trade today after the company reported a...
RPG Life Sciences Ltd (BOM:532983) Q2 2026 Earnings Call Highlights: Strong Domestic Growth and ...
RPG Life Sciences Ltd (BOM:532983) Q2 2026 Earnings Call Highlights: Strong Domestic Growth and Strategic Initiatives Amid Challenges
Q2 2026 RPG Life Sciences Ltd Earnings Call Transcript
Q2 2026 RPG Life Sciences Ltd Earnings Call Transcript
RPG Life Sciences Transcript: Q2 25/26
Domestic formulations grew 17.2% YOY in Q2, outpacing the market, while API business is set to recover in H2 after a fire. EBITDA margin remains strong at 24%, and the company maintains a debt-free, cash-rich position, with continued expansion and digital initiatives.
RPG Life Sciences drops nearly 6% following Q1 results
Shares of RPG Life Sciences Ltd fell 5.82% to ₹2,346.90 in early trade on Monday after the company posted a marginal decline in net profit for the quarter ended June 2025. The stock opened weak and qu...
RPG Life Sciences Transcript: Q4 24/25
Q4 FY25 saw revenue up 12.7% and strong profit growth, with margins expanding across all segments. Cash surplus reached INR 266 crore, and all business lines are set for further growth, supported by modernized plants and a robust product pipeline.
RPG Life Sciences shares surge nearly 8% after Q4 net profit jumps 786% on one-time land gain
Shares of RPG Life Sciences rose 7.64% to ₹2,277.60 on Monday, climbing ₹161.70 from the previous close of ₹2,115.90. The stock was among the top gainers on the NSE following the announcement of the c...
RPG Life Sciences surges 9.36% on robust Q3 FY25 earnings; net profit up 32% YoY
RPG Life Sciences Limited’s stock rallied 9.36% to ₹2,279.20 on the NSE as of 9:57 AM, driven by its strong Q3 FY25 results. The company reported a 31.99% year-on-year increase in net profit to ₹34.93...
Stocks in focus today, January 27, 2025: JK Cement, Balkrishna Industries, Shakti Pumps, Yes Bank, KEC International, Trident, RPG Life Sciences, Jubilant Pharmova
Several mid- and small-cap companies have released key updates today, focusing on their Q3 performance, acquisitions, and new business orders. JK Cement: Q3 sales volumes grew 5%, and the company anno...
RPG Life Sciences reports fire incident at manufacturing plant in Navi Mumbai
At present, the company is investigating the cause of the fire and assessing the extent of the damage caused. RPG Life Sciences reassured stakeholders that it has adequate insurance coverage for the a...
RPG Life Sciences Transcript: Q2 24/25
Achieved 14.7% growth, double the market rate, with record EBITDA margin of 27.8% and all segments posting double-digit growth. Strategic focus on international expansion, R&D, and M&A, supported by strong cash surplus and plant upgrades.
RPG Life Sciences Transcript: Status Update
INR 32.2 crore will be paid as a one-time expense in Q2 for MIDC transfer charges, while INR 144.9 crore from the assignment of API plant land is expected to be recognized in Q3, supporting future M&A and growth initiatives. Cash surplus will be used for expansion and acquisitions.